Dysesthesia is the signal that has drawn most clinical attention, because it does not feature in the semaglutide or tirzepatide profiles
Duration of treatment is typically determined by the doctor through an evaluation of blood test results
Limitations of Use: Compounded tirzepatide should not be used in combination with other tirzepatide-containing products or any other GLP-1/GIP receptor agonist medicines
When working with this concentration, round to the nearest measurable increment on your syringe
Methods: 25 women with PCOS and obesity, aged 33.7 5.3 years (mean SD), were treated with once-weekly subcutaneous semaglutide 1.0 mg as an adjunct to metformin 2000 mg/day and lifestyle intervention for 16 weeks
If new legislation or FDA policy changes emerge from the case, broader reforms could be implemented, affecting how shortages are determined and how compounding exemptions are granted in the future